Investors
Morphogenesis is a privately held company with an intellectual property portfolio centered around cellular technologies. The market value for cell therapies is expected to reach $78B by the year 2010, and Arrowhead Publishers has estimated that in addition, cancer vaccines could grab $6B in annual sales, about 1 tenth of the annual cancer treatment market by that same time.
The Company's development pipeline is continually expanding and progressing, and the future applications of these technologies include cosmetic surgery, gene therapy, wound healing and the treatment of malignancies, degenerative, orthopedic and soft tissue disorders, genetic diseases, as well as infectious diseases like AIDS. This means licensing opportunities for potential strategic partners, investment opportunities for potential investors and continued success for Morphogenesis and its current shareholders.
Contact Information